Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pneumocystis carinii

S J Levine1

  • 1Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland, USA.

Clinics in Chest Medicine
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Pneumocystis pneumonia (PCP) incidence in HIV patients has decreased due to chemoprophylaxis. However, PCP remains a significant lung infection risk for those not receiving prophylaxis or experiencing breakthrough infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A CCL24-dependent pathway augments eosinophilic airway inflammation in house dust mite-challenged Cd163(-/-) mice.

Mucosal immunology·2015
Same author

Isolation rearing significantly perturbs brain metabolism in the thalamus and hippocampus.

Neuroscience·2012
Same author

Polymorphisms in candidate asthma genes.

The American journal of the medical sciences·2001
Same author

Pneumocystis carinii pneumonia in patients without HIV infection.

The American journal of the medical sciences·2001
Same author

Tumor necrosis factor-alpha stimulates human Clara cell secretory protein production by human airway epithelial cells.

American journal of respiratory cell and molecular biology·1998
Same author

The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes.

Infection and immunity·1997
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Immunology

Background:

  • Pneumocystis carinii pneumonia (PCP) was a major opportunistic infection in HIV/AIDS patients.
  • Advances in understanding and chemoprophylaxis have reduced PCP incidence since the late 1980s.

Purpose of the Study:

  • To provide a comprehensive review of Pneumocystis carinii pneumonia (PCP) in HIV-seropositive patients.
  • To cover the history, biology, clinical aspects, prognosis, treatment, and prevention of PCP.

Main Methods:

  • Literature review and synthesis of existing research on PCP in HIV-seropositive individuals.
  • Analysis of historical trends, biological mechanisms, clinical presentations, and therapeutic strategies.

Main Results:

Related Experiment Videos

  • Widespread chemoprophylaxis has led to a decline in PCP incidence among HIV-infected individuals.
  • PCP remains a critical cause of pulmonary disease in HIV-seropositive patients lacking prophylaxis or experiencing treatment failures.

Conclusions:

  • Despite reduced incidence, PCP is still a significant threat in the HIV-seropositive population.
  • Effective management requires understanding of risk factors, clinical manifestations, and appropriate therapeutic and prophylactic interventions.